- Home
- IDYA vs BLX Comparison
IDYA vs BLX Comparison
Compare IDYA & BLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- BLX
- Stock Information
- Founded
- IDYA 2015
- BLX 1977
- Country
- IDYA United States
- BLX Panama
- Employees
- IDYA N/A
- BLX N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- BLX Commercial Banks
- Sector
- IDYA Health Care
- BLX Finance
- Exchange
- IDYA Nasdaq
- BLX Nasdaq
- Market Cap
- IDYA 1.5B
- BLX 1.4B
- IPO Year
- IDYA 2019
- BLX N/A
- Fundamental
- Price
- IDYA $21.22
- BLX $41.27
- Analyst Decision
- IDYA Strong Buy
- BLX
- Analyst Count
- IDYA 12
- BLX 0
- Target Price
- IDYA $54.27
- BLX N/A
- AVG Volume (30 Days)
- IDYA 1.5M
- BLX 115.1K
- Earning Date
- IDYA 05-06-2025
- BLX 05-05-2025
- Dividend Yield
- IDYA N/A
- BLX 6.04%
- EPS Growth
- IDYA N/A
- BLX 13.55
- EPS
- IDYA N/A
- BLX 5.60
- Revenue
- IDYA $7,000,000.00
- BLX $289,499,000.00
- Revenue This Year
- IDYA $68.39
- BLX $13.23
- Revenue Next Year
- IDYA $324.54
- BLX $7.79
- P/E Ratio
- IDYA N/A
- BLX $7.32
- Revenue Growth
- IDYA N/A
- BLX 13.37
- 52 Week Low
- IDYA $13.45
- BLX $27.37
- 52 Week High
- IDYA $44.42
- BLX $42.88
- Technical
- Relative Strength Index (RSI)
- IDYA 65.40
- BLX 59.65
- Support Level
- IDYA $19.26
- BLX $40.91
- Resistance Level
- IDYA $20.46
- BLX $41.66
- Average True Range (ATR)
- IDYA 1.01
- BLX 0.72
- MACD
- IDYA 0.24
- BLX -0.00
- Stochastic Oscillator
- IDYA 99.55
- BLX 80.41
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.